←Back to Expert Scholars
Translational Medicine / 转化医学GVHD, Treg Therapy
John Koreth
MBBS, DPhil
🏢Dana-Farber Cancer Institute🌐USA
Associate Professor of Medicine
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
John Koreth pioneered low-dose IL-2 therapy to expand regulatory T cells and treat chronic GVHD at Dana-Farber. His work bridges immune tolerance biology with clinical trials. He is a leader in Treg-based GVHD therapeutics.
Share:
🧪Research Fields 研究领域
chronic GVHD
Treg therapy
low-dose IL-2
allogeneic HCT
immune tolerance
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 John Koreth 的研究动态
Follow John Koreth's research updates
留下邮箱，当我们发布与 John Koreth（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment